Syn-Ake
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Syn-Ake is marketed as the “snake-venom cream” ingredient — a synthetic peptide designed to mimic a genuine venom-derived molecule rather than an actual venom extract, in the same neuromuscular-relaxer family as Argireline (acetyl Hexapeptide-3), SNAP-8, Vialox, and Pentapeptide-18.
What does it do in my body?
Syn-Ake mimics Waglerin-1, a peptide from temple-viper venom, to competitively antagonize nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction, reducing contraction frequency — the same neuromuscular-junction target as Vialox, approached from a different molecular angle.
How can it help me?
- Where the science stands: Anecdotal, but with 1 in-vitro/in-silico study; OHM’s 0035 grading is more favorable (Tier C) than the bare public record
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-effect data specific to Syn-Ake was captured in the source profile. Family-wide read: topical delivery carries a benign safety record.
Regulatory status: Cosmetic-grade OTC topical ingredient — not an FDA-reviewed drug.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Topical-only cosmetic ingredient, formulated into leave-on serums alongside other neuro-relaxer peptides. No specific concentration was captured in the source profile.
What should I avoid combining — and what's synergistic?
Syn-Ake doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
The “snake-venom cream” ingredient — a synthetic mimic of a real temple-viper venom peptide, with a genuine (if shallow) in-vitro study behind it and a more favorable internal OHM read than the bare PubMed record shows.
| Class | Neuromuscular “Botox-like” relaxer — topical cosmetic peptide |
| Mechanism (one line) | Mimics Waglerin-1 (temple-viper venom) → competitively antagonizes nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction → reduced contraction frequency |
| Evidence base | Anecdotal, but with 1 in-vitro/in-silico study; OHM’s 0035 grading is more favorable (Tier C) than the bare public record |
| Safety record | Topical-only; benign safety record (Safety: green) |
| Regulatory status | Cosmetic-grade OTC skincare ingredient, not an FDA-reviewed drug |
What it is
Syn-Ake is marketed as the “snake-venom cream” ingredient — a synthetic peptide designed to mimic a genuine venom-derived molecule rather than an actual venom extract, in the same neuromuscular-relaxer family as Argireline (acetyl Hexapeptide-3), SNAP-8, Vialox, and Pentapeptide-18.
How it works
Syn-Ake mimics Waglerin-1, a peptide from temple-viper venom, to competitively antagonize nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction, reducing contraction frequency — the same neuromuscular-junction target as Vialox, approached from a different molecular angle.
What the research shows
The public profile grades Syn-Ake Anecdotal, but with a single study attached: “Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests” (Gok et al., 2024, PMID 37349941). No human trials are on the profile.
OHM’s internal 0035 categorization pass graded Syn-Ake Tier C / green and recommend-eligible, citing small topical RCTs reporting a muscle-relaxant effect on expression lines (per, attributed to Pentapharm/DSM) — a more favorable read than the bare PubMed record on its own.
Real-world protocol
Topical-only cosmetic ingredient, formulated into leave-on serums alongside other neuro-relaxer peptides. No specific concentration was captured in the source profile.
Side effects & management
No adverse-effect data specific to Syn-Ake was captured in the source profile. Family-wide read: topical delivery carries a benign safety record.
Regulatory status
Cosmetic-grade OTC topical ingredient — not an FDA-reviewed drug.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 1 in-vitro study, 0 human trials. Study cited: Gok et al., 2024, PMID 37349941.
- OHM tier/safety grading: Tier C / green / recommend-eligible, citing Pentapharm/DSM topical RCTs.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Argireline (acetyl Hexapeptide-3) · SNAP-8 · Vialox · Pentapeptide-18
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 1 in-vitro study, 0 human trials. Study cited: Gok et al., 2024, PMID 37349941.
- OHM tier/safety grading: Tier C / green / recommend-eligible, citing Pentapharm/DSM topical RCTs.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Argireline (acetyl Hexapeptide-3) · SNAP-8 · Vialox · Pentapeptide-18